Skip to main content

Table 1 Clinical characteristics of the patients with benign biliary tract disease (control) and cholangiocarcinoma

From: Detection of serum MMP-7 and MMP-9 in cholangiocarcinoma patients: evaluation of diagnostic accuracy

  Control
(n = 36)
Cholangiocarcinoma
(n = 44)
p value
Age (Yr) 54 ± 14.5 59 ± 12.9 0.130
Sex (Male:Female) 15:16 26:18 0.248#
Total bilirubin (mg/dL) 4.2 ± 5.53 14.6 ± 11.34 <0.001*
Direct bilirubin (mg/dL) 2.6 ± 3.75 10.3 ± 8.47 <0.001*
Albumin (g/dL) 3.8 ± 0.61 3.1 ± 0.68 0.050
Globulin (g/dL) 3.6 ± 0.73 4.1 ± 0.93 0.253
AST (U/L) 65.4 ± 53.80 183.9 ± 378.82 0.012*
ALT (U/L) 75.0 ± 77.72 101.4 ± 14.49 0.615
ALP (IU/L) 318.6 ± 349.65 551.8 ± 526.04 0.001*
  1. Quantitative variables are presented as the means ± standard deviation. #; Pearson Chi-square was used to compare between two groups, *; the level of serum total bilirubin, direct bilirubin, AST and ALP were significantly higher in cholangiocarcinoma patients than in controls (Mann-Whitney U test; p < 0.05).